Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials
From MaRDI portal
Publication:3842893
DOI10.1080/03610929808832163zbMath0915.62089MaRDI QIDQ3842893
Edward L. Korn, T. Timothy Chen, Michael Friedman, Harry S. Wieand, Richard M. Simon, Stewart J. Anderson, Anne S. Lindblad, Harold O. Jun. Douglass, Bernard Fisher, J. Michael Hamilton
Publication date: 30 June 1999
Published in: Communications in Statistics - Theory and Methods (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1080/03610929808832163
62P10: Applications of statistics to biology and medical sciences; meta analysis
Cites Work
- Inference using surrogate outcome data and a validation sample
- A Stochastic Model for Censored-Survival Data in the Presence of an Auxiliary Variable
- Using surrogate failure time data to increase cost effectiveness in clinical trials
- A Two-Stage Procedure for Survival Studies with Surrogate Endpoints
- Analyzing survival data in conjunction with time-dependent surrogate endpoints in clinical trials